What to know
The September 4th ZOHU Call will take place from 2:00-3:00 pm ET. A video recording will be posted within 30 days after the call. To join online, enter the passcode: zohu@sep4
1 hour
Sep 4, 2024
2:00 PM - 3:00 PM ET
Webinar details
Presentation topics
- Rocky Mountain Spotted Fever: A Disease of Binational Concern
- Building Momentum for Public Health Impact: The National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People
- Lymphocytic Choriomeningitis Virus
Join the Live Call (Webcast)
Listen only by phone
US: +1 669 254 5252 US (San Jose) or +1 646 828 7666 US (New York) or +1 646 964 1167 US (US Spanish Line) or +1 551 285 1373 US (New Jersey) or +1 669 216 1590 US (San Jose) or +1 415 449 4000 US (US Spanish Line)
Webinar ID: 161 880 6728
Passcode: 566727253
International numbers available: https://cdc.zoomgov.com/u/adVFpJ3lQ3
Featuring
Continuing Education (CE)
Visit CDC Train to receive continuing education (CE).
Webcast (Live)
- Course Name: WC4565(SC)-090424
- Registration Code: ZOHUwebcast
- Start Date: September 4, 2024
- End Date: October 7, 2024
Web-on-Demand (Recording)
- Course Name: WD4565(SC)-090424
- Start Date: October 8, 2024
- End Date: October 8, 2026
Series objectives
1. Identify an implication for human, animal, and environmental health.
2. Identify a One Health approach strategy for prevention of public health threats.
3. Identify a One Health approach strategy for detection of public health threats.
4. Identify a One Health approach strategy for responding to public health threats.
5. List two ways to improve collaborative practice across the public healthcare team.
Disclosures
In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept commercial or in-kind support for this activity.